Nexavar 200 mg film-coated tablets

DRUG4 trials

Conditions

Acute myeloid leukemiaAdvanced hepatocellular carcinoma (HCC)Chronic myelomonocyte leukemiaHepatocellular carcinomaMyelodysplastic syndromeadvanced-stage malignancies harboring BRAF mutations with impaired kinase activity

Phase 1

Cross-institutional, prospective, open label, single group basket study of combined CRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutations with impaired kinase activity - SORATRAM

RecruitingCTIS2024-512887-77-00

Medical Center - University Of Freiburgadvanced-stage malignancies harboring BRAF mutations with impaired kinase activity

Start: 2020-10-21Target: 30Updated: 2025-12-18

Phase 2

Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial

CompletedCTIS2023-509092-16-00

Akershus University HospitalAcute myeloid leukemia, Chronic myelomonocyte leukemia, Myelodysplastic syndrome

End: 2025-11-27Target: 33Updated: 2024-10-18

Phase 3

A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA)

Active, not recruitingCTIS2024-512212-21-00

AstraZeneca ABAdvanced hepatocellular carcinoma (HCC)

Start: 2017-11-28Target: 302Updated: 2025-12-16

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Active, not recruitingCTIS2024-516479-34-00

Exelixis Inc.Hepatocellular carcinoma

Start: 2019-05-17Target: 7Updated: 2025-11-04

Related Papers

Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial).